喉部肌张力障碍:术语、病理生理与研究优先方向的多学科更新
美国国立卫生研究院召集多学科专家召开为期一天的研讨会,回顾喉部肌张力障碍的术语与病理生理进展并识别临床与研究空白。专家组一致同意采用「喉部肌张力障碍」替代「痉挛性发声障碍」,认定其为多因素、表型异质的孤立性肌张力障碍,病因未知而病理生理可能涉及大规模脑网络功能与结构紊乱。研究优先方向包括寻找疾病特异性生物标志物与明确神经网络关键节点以开发靶向治疗。
要点
- 建议统一采用「喉部肌张力障碍」替代「痉挛性发声障碍」。
- 该病为多因素、表型异质的孤立性肌张力障碍,病因仍未知。
- 研究优先方向为生物标志物、网络关键节点与多中心协作。
核心结论
- 专家组一致同意采用「喉部肌张力障碍」替代「痉挛性发声障碍」以反映对该病特征认识的最新进展。
- 喉部肌张力障碍被视为多因素、表型异质的孤立性肌张力障碍,病因未知而病理生理可能涉及大规模脑网络功能与结构紊乱。
研究设计与样本
- 美国国立卫生研究院召集多学科专家小组举行为期一天的研讨会,回顾该病术语与自2005年类似研讨会以来的病理生理进展。
- 参与者识别临床与研究空白并提出未来方向建议。
主要发现
- 专家组一致同意采用「喉部肌张力障碍」替代「痉挛性发声障碍」。
- 喉部肌张力障碍被认定为多因素、表型异质的孤立性肌张力障碍,病因仍未知。
- 其病理生理可能涉及大规模功能与结构脑网络紊乱。
- 当前挑战包括缺乏经临床验证的诊断标志物与结局指标,以及针对该病病理生理的治疗匮乏。
关键数值与推荐
- 专家组一致同意采用「喉部肌张力障碍」替代「痉挛性发声障碍」。
- 喉部肌张力障碍被认定为多因素、表型异质的孤立性肌张力障碍。
- 研究优先方向包括识别疾病特异性生物标志物以开发新诊断工具与统一治疗结局指标。
- 研究优先方向包括阐明致症状或调症状的神经网络关键节点以开发针对病理生理的靶向治疗。
- 鉴于该病罕见,未来快速研究进展可能需依托多中心、国家和国际协作。
临床怎么用
- 临床交流与记录中采用「喉部肌张力障碍」这一术语。
- 将该病作为多因素、表型异质的孤立性肌张力障碍进行管理。
- 关注诊断标志物与结局指标的缺失,并留意靶向网络病理生理的治疗方向。
局限性
- 该病罕见,可能限制单中心研究与快速进展。
- 缺乏经临床验证的诊断标志物与结局指标。
- 针对该病病理生理的治疗匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To delineate research priorities for improving clinical management of laryngeal dystonia, the NIH convened a multidisciplinary panel of experts for a 1-day workshop to examine the current progress in understanding its etiopathophysiology and clinical care. METHODS: The participants reviewed the current terminology of disorder and discussed advances in understanding its pathophysiology since a similar workshop was held in 2005. Clinical and research gaps were identified, and recommendations for future directions were delineated. RESULTS: The panel unanimously agreed to adopt the term "laryngeal dystonia" instead of "spasmodic dysphonia" to reflect the current progress in characterizations of this disorder. Laryngeal dystonia was recognized as a multifactorial, phenotypically heterogeneous form of isolated dystonia. Its etiology remains unknown, whereas the pathophysiology likely involves large-scale functional and structural brain network disorganization. Current challenges include the lack of clinically validated diagnostic markers and outcome measures and the paucity of therapies that address the disorder pathophysiology. CONCLUSION: Research priorities should be guided by challenges in clinical management of laryngeal dystonia. Identification of disorder-specific biomarkers would allow the development of novel diagnostic tools and unified measures of treatment outcome. Elucidation of the critical nodes within neural networks that cause or modulate symptoms would allow the development of targeted therapies that address the underlying pathophysiology. Given the rarity of laryngeal dystonia, future rapid research progress may be facilitated by multicenter, national and international collaborations.
引用
- Simonyan K, Barkmeier-Kraemer J, Blitzer A, et al. Laryngeal Dystonia: Multidisciplinary Update on Terminology, Pathophysiology, and Research Priorities. Neurology. 2021. PMID: 33858994. doi:10.1212/WNL.0000000000011922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。